The global intradermal injection market is expected to surpass an impressive valuation of US$ 3,878 Million in 2022 and is projected to exhibit a compound annual growth rate (CAGR) of 10.8% from 2022 to 2032.
In recent years, technological advancements have led to the development of surgical approaches with the aim to minimize waste and achieve better results. The reusable intradermal devices result in low waste generation, having a net positive effect on the productivity of an economy.
Along with this, the results of several meta-analyses prove that intradermal delivery of drugs reduces the intensity of adverse events. The factors mentioned above indicate the favorable condition for the rapid growth of this segment in the future.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2022) | US$ 3,878 Million |
| Anticipated Forecast Value (2032) | US$ 10,814.47 Million |
| Projected Growth Rate (2022 to 2032) | 10.8% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Over the past two decades, there has been an increase in the demand for intradermal injections. This is due to the rising incidence of diseases with a simultaneous increase in the use of intradermal vaccination and aesthetic procedures.
Furthermore, the growing burden of chronic diseases has led to a rise in the overall use of syringes, particularly disposable syringes, intradermal jet injectors, microinjections, and ballistic intradermal injection treatment and diagnostic purposes. The global demand for Intradermal Injections is projected to increase at a CAGR of 10.8% during the forecast period between 2022 and 2032, reaching a total of US$ 10,814.47 Million in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 8%.
Growing Prevalence of Chronic Diseases, Increase in Aesthetic Surgical Procedures to Catalyse Intradermal Injection Uptake
The rising prevalence rate of tuberculosis is expected to promote the growth rate of the intradermal injection market. As per the data of WHO, tuberculosis is the 13th leading cause of death, and about 10 million cases of TB have been recorded every year, which resulted in a sudden rise in the diagnostic rate of TB during the last decade. This is one of the major factors that act as one of the leading reasons for increasing the intradermal injection market size of tuberculin syringes.
In addition to this, the number of aesthetic procedures is increasing rapidly in North America and Europe. The intradermal vaccination reduces the potential dose of antigens, improves the immune response, and decreases the anxiety associated with the vaccination. Moreover, aesthetic procedures are the leading segment of local aesthetic procedures, increasing the demand for intradermal injections.
Almost all vaccines require cold chain distribution and storage, which further limits resources or refrigerator space in a healthcare setting. Globally, approximately 17.4 million people are prone to rabies through animal bites annually. It occurs in more than 150 territories and countries, rabies is a viral disease that can cause encephalitis when transmitted to humans. Intradermal injections immensely help in lowering the cost of cell-derived vaccines for pre-exposure to rabies. The cost-savings with intradermal injections for rabies create immense opportunities for the intradermal injections market.
Principal Consultant
Unfavorable Government Provisions to Hinder Market Growth
Despite the advantages shown through various clinical studies, there are various barriers that hinder the usage of intradermal injections. The major world economies across Europe, the United States, and other developed regions rely on single-dose formats and have government funding or private insurance for vaccination. Emerging markets are anticipated to favor multi-dose formats and are limited by availability and cost of supply.
Increased Prevalence of Diseases to drive the adoption of intradermal Injection
According to the American Cancer Society’s 2022 report, over 1.9 million new cancers are expected to be recorded in the United States in 2022. Also, as per the same source, the risk of having cancer rises dramatically as one gets older, and in the United States, 80% of cancer patients are 55 or older, with 57% being 65 or older. These figures tell that the growing geriatric population is expected to have a significant positive impact on the growth of the market.
Not just this but according to the International Diabetes Federation’s report of December 2021, about 32.2 million people were living with diabetes in the United States in 2021, and this number is estimated to increase to 36.3 million by 2045. This expansion in the diabetes patient pool is expected to boost growth in intradermal injection in the United States.
The Increasing Prevalence of Diabetes is Spurring Demand for Intradermal Injection
As per the International Diabetes Federation (IDF) Diabetes Atlas 2021, the age-adjusted comparative prevalence of diabetes in the United Kingdom for 2021, 2030, and 2045 were estimated as 6.3%, 7.0%, and 7.5% respectively. Therefore, the gradual rise in the prevalence of diabetes is expected to increase the market demand.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Normal Sized Needles to Lead the Method Type of Intradermal Injection
Based on the method, the intradermal injection market is segmented into normal-sized needles, short needles, and without needles. As per our research, normal-sized needles dominate the market, while the short-needle segment is estimated to register considerable growth.
Tuberculin Skin Test Segment is Estimated to Hold the Largest Share
Based on application, the market is segmented into tuberculin skin tests, allergy tests, local aesthetics, and others. The tuberculin skin test segment is estimated to hold the largest share of the market in 2022, accounting for 58% of total demand, while the local aesthetic segment is expected to register the highest CAGR during the forecast period.
Key players in the Intradermal Injection market are Becton Dickinson, Cardinal Health, West Pharmaceuticals Services, Terumo Corporation, Nanopass, Pharmajet, Idevax, Enusung, Crossject, and Hindustan Syringes and Medical Devices.
| Report Attribute | Details |
|---|---|
| Market Value in 2022 | US$ 3,878 Million |
| Market Value in 2032 | US$ 10,814.47 Million |
| Growth Rate | CAGR of 10.8% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2017 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
FMI projects the global Intradermal Injection market to expand at a 10.8% value CAGR by 2032.
The global Intradermal Injection market is estimated at a market value of US$ 2.5 Billion.
The global Intradermal Injection market is expected to garner a market value of US$ 10814.47 Million.
FMI has projected North America to be one of the key regions for the Intradermal Injection market.
Becton Dickinson, Cardinal Health, West Pharmaceuticals services, Terumo Corporation, Nanopass, Pharmajet, Idevax, Enusung, Crossject, and Hindustan Syringes and Medical Devices.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Method
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ million) Analysis By Method, 2017 to 2021
5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Method, 2022 to 2032
5.3.1. Normal Sized Needles
5.3.2. Short Needle
5.3.2.1. Intradermal Microinjection
5.3.2.2. Microneedle Arrays
5.3.2.3. Tattoo Devices
5.3.3. Without Needle
5.3.3.1. Intradermal Liquid Jet Devices
5.3.3.2. Ballistic Intradermal Injectors
5.4. Y-o-Y Growth Trend Analysis By Method, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Method, 2022 to 2032
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Application
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ million) Analysis By Application, 2017 to 2021
6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Application, 2022 to 2032
6.3.1. Tuberculin Skin Test
6.3.2. Allergy Test
6.3.3. Local Aesthetics
6.3.4. Others
6.4. Y-o-Y Growth Trend Analysis By Application, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By Application, 2022 to 2032
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ million) Analysis By End User, 2017 to 2021
7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By End User, 2022 to 2032
7.3.1. Hospitals
7.3.2. Diagnostic Laboratories
7.3.3. Academics And Research Institutes
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2021
7.5. Absolute $ Opportunity Analysis By End User, 2022 to 2032
8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ million) Analysis By Region, 2017 to 2021
8.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2022 to 2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. Middle East and Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
9.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. The USA
9.2.1.2. Canada
9.2.2. By Method
9.2.3. By Application
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Method
9.3.3. By Application
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Method
10.2.3. By Application
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Method
10.3.3. By Application
10.3.4. By End User
10.4. Key Takeaways
11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Method
11.2.3. By Application
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Method
11.3.3. By Application
11.3.4. By End User
11.4. Key Takeaways
12. South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Method
12.2.3. By Application
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Method
12.3.3. By Application
12.3.4. By End User
12.4. Key Takeaways
13. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Method
13.2.3. By Application
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Method
13.3.3. By Application
13.3.4. By End User
13.4. Key Takeaways
14. Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
14.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
14.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Method
14.2.3. By Application
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Method
14.3.3. By Application
14.3.4. By End User
14.4. Key Takeaways
15. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
15.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
15.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Method
15.2.3. By Application
15.2.4. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Method
15.3.3. By Application
15.3.4. By End User
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. The USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2021
16.1.2.1. By Method
16.1.2.2. By Application
16.1.2.3. By End User
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2021
16.2.2.1. By Method
16.2.2.2. By Application
16.2.2.3. By End User
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2021
16.3.2.1. By Method
16.3.2.2. By Application
16.3.2.3. By End User
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2021
16.4.2.1. By Method
16.4.2.2. By Application
16.4.2.3. By End User
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2021
16.5.2.1. By Method
16.5.2.2. By Application
16.5.2.3. By End User
16.6. The United Kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2021
16.6.2.1. By Method
16.6.2.2. By Application
16.6.2.3. By End User
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2021
16.7.2.1. By Method
16.7.2.2. By Application
16.7.2.3. By End User
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2021
16.8.2.1. By Method
16.8.2.2. By Application
16.8.2.3. By End User
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2021
16.9.2.1. By Method
16.9.2.2. By Application
16.9.2.3. By End User
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2021
16.10.2.1. By Method
16.10.2.2. By Application
16.10.2.3. By End User
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2021
16.11.2.1. By Method
16.11.2.2. By Application
16.11.2.3. By End User
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2021
16.12.2.1. By Method
16.12.2.2. By Application
16.12.2.3. By End User
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2021
16.13.2.1. By Method
16.13.2.2. By Application
16.13.2.3. By End User
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2021
16.14.2.1. By Method
16.14.2.2. By Application
16.14.2.3. By End User
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2021
16.15.2.1. By Method
16.15.2.2. By Application
16.15.2.3. By End User
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2021
16.16.2.1. By Method
16.16.2.2. By Application
16.16.2.3. By End User
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2021
16.17.2.1. By Method
16.17.2.2. By Application
16.17.2.3. By End User
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2021
16.18.2.1. By Method
16.18.2.2. By Application
16.18.2.3. By End User
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2021
16.19.2.1. By Method
16.19.2.2. By Application
16.19.2.3. By End User
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2021
16.20.2.1. By Method
16.20.2.2. By Application
16.20.2.3. By End User
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2021
16.21.2.1. By Method
16.21.2.2. By Application
16.21.2.3. By End User
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Method
17.3.3. By Application
17.3.4. By End User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Becton Dickinson
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Cardinal Health
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. West Pharmaceuticals services
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Terumo Corporation
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Nanopass
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Pharmajet
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Idevax
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Enusung
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Crossject
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Hindustan Syringes
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Intradermal Injection Market
